This study is currently not recruiting participants.

Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV

J
Jeanne Schilder, MD

Primary Investigator

Not Recruiting
18 years - 100 years
Female
Phase N/A
1 Location

Brief description of study

The purpose of the study is to compare the disease free survival (DFS) of ADXS11-001 to placebo administered following CCRT with curative intent in subjects with HRLACC.

Detailed description of study

This is a double-blind, placebo-controlled randomized study of ADXS11 001 administered in the adjuvant setting after completion of cisplatin-based CCRT in subjects with locally advanced cervical cancer at higher risk for recurrence (HRLACC), or death.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: cervical cancer
  • Age: 18 years - 100 years
  • Gender: Female
Updated on 01 Aug 2024. Study ID: 1701959811 (GOG-3009)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the Study Team